截至4月21日10时17分，舒泰神股价封于20.04%涨停，最新报10.90元，总市值达52.08亿元，封单金额超10亿元，成交额4.93亿元，换手率10.41%。
消息面上，公司董事长周志文在4月16日业绩说明会上表示，舒泰神“处于有史以来最好的发展时期”，并透露多项在研项目进展：STSP-0601（血友病治疗药）、BDB-001（自身免疫性疾病治疗药）及STSA-1002（急性呼吸窘迫综合征治疗药）等已进入临床中后期，其中2项获突破性疗法认定。此外，公司正通过BD策略推动在研品种对外合作，并应用AI技术优化抗体设计及药物开发流程。
不过，财务数据显示，舒泰神已连续5年亏损，2024年归母净利润为-1.45亿元，虽同比减亏，但经营压力仍存。
风险提示：创新药研发存在不确定性，市场竞争及业绩亏损或对股价产生影响。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.